Cellectis – CLLS

Cellectis S A.

infoCellectis is a micro cap stock with a total market cap of 108.26M.

infoThey trade on the NASDAQ and had their IPO 8 years and 4 months ago.

infoCellectis currently employs 231 people.

infoAs of Wednesday, Aug 23 2023, Cellectis’s share price is $1.9477.

newspaper
News Relating to Cellectis
Seeking Alpha
Cellectis SA (CLLS) Q2 2023 Earnings Call Transcript

Friday Aug 04 2023 at 23:41

Cellectis SA (NASDAQ:CLLS ) Q2 2023 Earnings Conference Call August 5, 2023 8:00 AM ET Company Participants Arthur Stril – Chief Business Officer Andre Choulika – Co-Founder, CEO & Director Mark Frattini – SVP, Clinical Sciences & Chief Medical Officer Bing Wang – CFO Conference Call Participants Yigal Nochomovitz – Citigroup Gena Wang – Barclays Bank Yanan Zhu – Wells Fargo Anoumid Vaziri – Goldman Sachs Group Dev Prasad – Jefferies Hartaj Singh – Oppenheimer Jack Allen – Robert W. Baird Silvan Tuerkcan – JMP Securities Operator Good morning, and everyone, welcome to Cellectis Second Quarter 2023 Earnings Call.


GlobeNewsWire
Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023

Thursday Jul 27 2023 at 16:30

NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) — Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter ended June 30, 2023 on Thursday, August 3, 2023 after the close of the US market.


GlobeNewsWire
Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023

Thursday Apr 27 2023 at 16:30

NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter ended March 31, 2023, on Thursday, May 4, 2023 after the close of the US market.


GlobeNewsWire
Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023

Wednesday Mar 01 2023 at 16:30

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and year-end 2022 ending December 31st, 2022, on Wednesday, March 8, 2023, after the close of the US market.


MarketBeat
There’s a Lot of Upside For Emerging Gene-Editing Companies

Tuesday Feb 21 2023 at 09:16

Gene editing may be a relatively new industry, but it already has a lot of promise, especially for savvy biotech investors. Several gene editing companies have notable upsides, meaning that no matter how good or bad they might be doing right now, there is likely much more to come.


Pulse2
CLLS Stock: 23.01% Drop Explaination

Sunday Feb 05 2023 at 00:25

The stock price of Cellectis SA (NASDAQ: CLLS) fell by 23.01% in the most recent trading session. This is why.


InvestorPlace
7 CRISPR Stocks With the Best Long-Term Potential

Monday Jan 30 2023 at 19:10

CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis.


GlobeNewsWire
Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022

Thursday Dec 01 2022 at 16:40

NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) —  Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, will host a live webcast to review the Company’s clinical data on the AMELI-01 study (evaluating UCART123) presented at the ASH Annual Meeting, and provide a Company update, on December 13, 2022.


Seeking Alpha
Cellectis S.A. (CLLS) Q3 2022 Earnings Call Transcript

Friday Nov 04 2022 at 14:29

Cellectis S.A. (NASDAQ:CLLS ) Q3 2022 Earnings Conference Call November 4, 2022 8:00 AM ET Company Participants Arthur Stril – Chief Business Officer Andre Choulika – Chief Executive Officer Mark Frattini – Chief Medical Officer Bing Wang – Chief Financial Officer Conference Call Participants Gena Wang – Barclays Jack Allen – Baird Yigal Nochomovitz – Citigroup Salveen Richter – Goldman Sachs David Dai – SMBC Hartaj Singh – Oppenheimer & Company Yanan Zhu – Wells Fargo Ingrid Gafanhao – Kempen Operator Greetings, and welcome to the Cellectis Third Quarter 2022 Earnings Conference Call.


GlobeNewsWire
Cellectis to Report Third Quarter 2022 Financial Results

Thursday Oct 27 2022 at 16:37

NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter ended September 30th, 2022, on Thursday, November 3rd, 2022, after the close of the US market.


GlobeNewsWire
Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Wednesday Oct 05 2022 at 16:30

NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that pre-clinical data on TALEN®-edited smart CAR T-cells to overcome key challenges of targeting solid tumors, will be presented at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022), to be held in Boston, M.A. and virtually on November 8-12, 2022.


GlobeNewsWire
Cellectis Announces Participation in Four Upcoming Investor Conferences in September

Thursday Sep 01 2022 at 16:44

NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) —  Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that management plans to participate in four upcoming investor conferences.


Seeking Alpha
Cellectis S.A. (CLLS) CEO Andre Choulika on Q2 2022 Results – Earnings Call Transcript

Friday Aug 05 2022 at 14:36

Cellectis S.A. (NASDAQ:CLLS ) Q2 2022 Earnings Conference Call August 5, 2022 8:00 AM ET Company Participants Arthur Stril – Chief Business Officer Andre Choulika – Chief Executive Officer Bing Wang – Chief Financial Officer Conference Call Participants Gena Wang – Barclays Ashiq Mubarack – Citi Hartaj Singh – Oppenheimer Jack Allen – Baird David Dai – SMBC Silvan Tuerkcan – JMP Securities Nicolas Abbott – Wells Fargo Operator Good morning, everyone, and welcome to the Cellectis Second Quarter 2020 Earnings Call.


GlobeNewsWire
Cellectis to Report Second Quarter 2022 Financial Results

Thursday Jul 28 2022 at 16:30

NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter ended June 30th, 2022, on Thursday, August 4th, 2022, after the close of the US market.


The Motley Fool
Why Cellectis’ Shares Rose 22.7% This Week

Friday May 20 2022 at 19:35

The company bucked the recent downward trend for biotech companies.


Seeking Alpha
Cellectis S.A.’s (CLLS) CEO Andre Choulika on Q1 2022 Results – Earnings Call Transcript

Friday May 13 2022 at 11:11

Cellectis S.A. (NASDAQ:CLLS ) Q1 2022 Earnings Conference Call May 13, 2022 8:00 AM ET Company Participants Arthur Stril – Chief Business Officer Andre Choulika – Chief Executive Officer Carrie Brownstein – Chief Medical Officer Bing Wang – Chief Financial Officer Conference Call Participants Gena Wang – Barclays Yigal Nochomovitz – Citigroup Kelly Shi – Jeffries Jack Allen – Baird Hartaj Singh – Oppenheimer Raju Prasad – William Blair Silvan Tuerkcan – JMP Securities Operator Greeting and welcome to the Cellectis First Quarter 2022 Corporate Update and Earnings Call.


GlobeNewsWire
Cellectis to Report First Quarter 2022 Financial Results

Thursday May 05 2022 at 16:40

NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter ended March 31st, 2022, on Thursday, May 12th, 2022, after the close of the US market.


Seeking Alpha
Allogene: Speculative CAR T Biotech With Big Potential In Oncology

Friday Apr 01 2022 at 22:54

Allogene: Speculative CAR T Biotech With Big Potential In Oncology


GlobeNewsWire
Cellectis to Participate in Two Upcoming Investor Conferences in March

Friday Mar 11 2022 at 16:30

NEW YORK, March 11, 2022 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that management will participate in the Oppenheimer & Co. Annual Healthcare Conference, taking place March 15-17, 2022 as well as the Barclays Global Healthcare Conference, taking place March 15-17. Details for both presentations are below:


The Motley Fool
Why Cellectis Stock Rose 20.7% This Week

Thursday Mar 10 2022 at 21:40

Investors saw a bargain when the stock hit its 52-week low early in the week.


Seeking Alpha
Cellectis S.A. (CLLS) CEO Andre Choulika on Q4 2021 Results – Earnings Call Transcript

Friday Mar 04 2022 at 16:37

Cellectis S.A. (CLLS) CEO Andre Choulika on Q4 2021 Results – Earnings Call Transcript


Proactive Investors
Arovella Therapeutics appoints senior preclinical development and translational medicine expert to strengthen team

Monday Jan 24 2022 at 20:25

Arovella Therapeutics Ltd (ASX:ALA) has welcomed Dr Mini Bharathan to the executive team to lead preclinical trials of the newly acquired DKK1 peptide targeting technology and its CAR19-iNKT cell therapy technologies. With more than 15 years of experience in the field of immunology under her belt, Dr Bharathan has spent the last 12 years working in the development of cell therapies with various organisations, such as the US Department of Health, Celgene and Cellectis (NASDAQ:CLLS) (Cellectis (NASDAQ:CLLS)).


Stockmarketcom
Good Stocks To Invest In Right Now? 4 Health Care Stocks To Check Out

Tuesday Dec 07 2021 at 14:36

While markets are cautiously optimistic on the Omicron variant, these health care stocks are still hard at work.


Benzinga
Cytovia, Cellectis Expand Collaboration On Gene-Edited Cancer Platform In China

Friday Nov 19 2021 at 07:09

Cytovia Therapeutics Inc and Cellectis SA (NASDAQ: CLLS) have expanded their collaboration of TALEN gene-edited iPSC-derived NK and CAR-NK cells. The expanded agreement will include a new CAR target and development in China by Cytovia’s joint venture entity, CytoLynx Therapeutics.


Seeking Alpha
Cellectis S.A. (CLLS) CEO Andre Choulika on Q3 2021 Results – Earnings Call Transcript

Friday Nov 05 2021 at 12:04

Cellectis S.A. (CLLS) CEO Andre Choulika on Q3 2021 Results – Earnings Call Transcript


GlobeNewsWire
Cellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Tuesday Oct 12 2021 at 16:35

NEW YORK, Oct. 12, 2021 (GLOBE NEWSWIRE) — Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for genetic diseases, announced today that pre-clinical data that support anti-tumor activity of UCARTMESO will be presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021), to be held in Washington, D.C. and virtually on November 10 to 14, 2021.


InvestorPlace
7 Gene Editing Stocks Promising to Change our DNA

Wednesday Sep 15 2021 at 12:45

Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market. The post 7 Gene Editing Stocks Promising to Change our DNA appeared first on InvestorPlace.


GlobeNewsWire
Cellectis Announces Participation in Five Investor Conferences

Thursday Aug 26 2021 at 16:34

NEW YORK, Aug. 26, 2021 (GLOBE NEWSWIRE) — Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for monogenic diseases, today announced that management plans to participate in five virtual investor conferences.


Seeking Alpha
Cellectis S.A. (CLLS) CEO André Choulika on Q2 2021 Results – Earnings Call Transcript

Friday Aug 06 2021 at 15:33

Cellectis S.A. (CLLS) CEO André Choulika on Q2 2021 Results – Earnings Call Transcript


GlobeNewsWire
Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2021

Thursday Aug 05 2021 at 16:30

• Preliminary translational data validate UCARTCS1 as a promising potential therapy for relapsed orrefractory multiple myeloma patients.

crisis_alert
Cellectis Bankruptcy Risk

The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.

Learn more at Investopediaopen_in_new

warning

Cellectis’s Altman Z-score is -2.43 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.

Derived from SEC.GOV filing dataopen_in_new

account_balance
Cellectis Insider Trading

Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.

Learn more at Investopediaopen_in_new

help

Over the last 3 months, there has been no insider trading in Cellectis.

Derived from SEC.GOV filing dataopen_in_new

insights
Debt & Income Analysis

Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.

Learn more at WallStreetPrepopen_in_new

sentiment_very_satisfied

Cellectis’s Income Quality of 0.87 is greater than its Industry Group of 0.69 (26.1% greater)

sentiment_very_satisfied

Cellectis’s Income Quality of 0.87 is greater than its Major Industry Group of 0.71 (22.5% greater)

sentiment_very_satisfied

Cellectis’s Income Quality of 0.87 is greater than its Sector of 0.75 (16.0% greater)

Derived from SEC.GOV filing dataopen_in_new


Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.

Learn more at Investopediaopen_in_new

warning

Cellectis’s Current Ratio of 2.69 is lower than its Industry Group of 4.76 (-43.5% lower)

warning

Cellectis’s Current Ratio of 2.69 is lower than its Major Industry Group of 4.32 (-37.7% lower)

sentiment_very_satisfied

Cellectis’s Current Ratio of 2.69 is in line with its Sector of 2.6 (3.5% greater)

Derived from SEC.GOV filing dataopen_in_new

query_stats
Value Analysis

PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.

Learn more at Investopediaopen_in_new

help

Cannot compare a negative PE Ratio (-1.19 & -1.27)

help

Cannot compare a negative PE Ratio (-1.19 & -1.1)

help

Cannot compare a negative PE Ratio (-1.19 & -0.4)

Derived from SEC.GOV filing dataopen_in_new


The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.

Learn more at Investopediaopen_in_new

sentiment_very_satisfied

Cellectis’s PB Ratio of 1.12 is lower than its Industry Group of 1.34 (-16.4% lower)

sentiment_very_satisfied

Cellectis’s PB Ratio of 1.12 is lower than its Major Industry Group of 1.4 (-20.0% lower)

sentiment_very_satisfied

Cellectis’s PB Ratio of 1.12 is lower than its Sector of 1.62 (-30.9% lower)

Derived from SEC.GOV filing dataopen_in_new

settings_suggest
Efficiency Analysis

ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.

Learn more at Investopediaopen_in_new

warning

Cellectis’s ROE of -0.94 is lower than its Industry Group of -0.44 (-113.6% lower)

warning

Cellectis’s ROE of -0.94 is lower than its Major Industry Group of -0.38 (-147.4% lower)

warning

Cellectis’s ROE of -0.94 is lower than its Sector of -0.03 (-3033.3% lower)

Derived from SEC.GOV filing dataopen_in_new


ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.

Learn more at Investopediaopen_in_new

sentiment_very_satisfied

Cellectis’s ROCE of -0.46 is in line with its Industry Group of -0.42 (-9.5% lower)

warning

Cellectis’s ROCE of -0.46 is lower than its Major Industry Group of -0.37 (-24.3% lower)

warning

Cellectis’s ROCE of -0.46 is lower than its Sector of -0.04 (-1050.0% lower)

Derived from SEC.GOV filing dataopen_in_new

More Stocks